Optimizing Cholesterol Treatment in Patients With Muscle Complaints

Robert S. Rosenson; Steven Baker; Maciej Banach; Kenneth M. Borow; Lynne T. Braun; Eric Bruckert; Liam R. Brunham; Alberico L. Catapano; Marshall B. Elam; G. B. John Mancini; Patrick M. Moriarty; Pamela B. Morris; Paul Muntner; Kausik K. Ray; Erik S. Stroes; Beth A. Taylor; Valerie H. Taylor; Gerald F. Watts; Paul D. Thompson

doi:https://doi.org/10.1016/j.jacc.2017.07.752

Optimizing Cholesterol Treatment in Patients With Muscle Complaints

Robert S. Rosenson, Steven Baker, Maciej Banach, Kenneth M. Borow, Lynne T. Braun, Eric Bruckert, Liam R. Brunham, Alberico L. Catapano, Marshall B. Elam, G. B. John Mancini, Patrick M. Moriarty, Pamela B. Morris, Paul Muntner, Kausik K. Ray, Erik S. Stroes, Beth A. Taylor, Valerie H. Taylor, Gerald F. Watts, Paul D. Thompson

Research output: Contribution to journal › Review article › Academic › peer-review

151 Citations (Scopus)

Abstract

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms

Original language	English
Pages (from-to)	1290-1301
Journal	Journal of the American College of Cardiology
Volume	70
Issue number	10
DOIs	https://doi.org/10.1016/j.jacc.2017.07.752
Publication status	Published - 2017

Access to Document

https://doi.org/10.1016/j.jacc.2017.07.752

Cite this

Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., Moriarty, P. M., Morris, P. B., Muntner, P., Ray, K. K., Stroes, E. S., Taylor, B. A., Taylor, V. H., Watts, G. F., & Thompson, P. D. (2017). Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 70(10), 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752

@article{bc513820ffd9423391f7ca04ba30699d,

title = "Optimizing Cholesterol Treatment in Patients With Muscle Complaints",

abstract = "Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms",

author = "Rosenson, {Robert S.} and Steven Baker and Maciej Banach and Borow, {Kenneth M.} and Braun, {Lynne T.} and Eric Bruckert and Brunham, {Liam R.} and Catapano, {Alberico L.} and Elam, {Marshall B.} and Mancini, {G. B. John} and Moriarty, {Patrick M.} and Morris, {Pamela B.} and Paul Muntner and Ray, {Kausik K.} and Stroes, {Erik S.} and Taylor, {Beth A.} and Taylor, {Valerie H.} and Watts, {Gerald F.} and Thompson, {Paul D.}",

year = "2017",

doi = "https://doi.org/10.1016/j.jacc.2017.07.752",

language = "English",

volume = "70",

pages = "1290--1301",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "10",

}

Rosenson, RS, Baker, S, Banach, M, Borow, KM, Braun, LT, Bruckert, E, Brunham, LR, Catapano, AL, Elam, MB, Mancini, GBJ, Moriarty, PM, Morris, PB, Muntner, P, Ray, KK, Stroes, ES, Taylor, BA, Taylor, VH, Watts, GF & Thompson, PD 2017, 'Optimizing Cholesterol Treatment in Patients With Muscle Complaints', Journal of the American College of Cardiology, vol. 70, no. 10, pp. 1290-1301. https://doi.org/10.1016/j.jacc.2017.07.752

TY - JOUR

T1 - Optimizing Cholesterol Treatment in Patients With Muscle Complaints

AU - Rosenson, Robert S.

AU - Baker, Steven

AU - Banach, Maciej

AU - Borow, Kenneth M.

AU - Braun, Lynne T.

AU - Bruckert, Eric

AU - Brunham, Liam R.

AU - Catapano, Alberico L.

AU - Elam, Marshall B.

AU - Mancini, G. B. John

AU - Moriarty, Patrick M.

AU - Morris, Pamela B.

AU - Muntner, Paul

AU - Ray, Kausik K.

AU - Stroes, Erik S.

AU - Taylor, Beth A.

AU - Taylor, Valerie H.

AU - Watts, Gerald F.

AU - Thompson, Paul D.

PY - 2017

Y1 - 2017

N2 - Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms

AB - Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms

U2 - https://doi.org/10.1016/j.jacc.2017.07.752

DO - https://doi.org/10.1016/j.jacc.2017.07.752

M3 - Review article

C2 - 28859793

SN - 0735-1097

VL - 70

SP - 1290

EP - 1301

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 10

ER -